Multiple testing of noninferiority hypotheses in active controlled trials

Journal of Biopharmaceutical Statistics

Volumn 14, Issue 2, 2004, Pages 327-335

  Hung, H M James ^a   Wang, Sue Jane ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Active controlled clinical trial; Maximum allowable noninferiority margin; Multiple testing

Indexed keywords

ACTIVE CONTROLLED TRIAL; ALPHA LEVEL; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROL; DATA ANALYSIS; HYPOTHESIS; INTENT TO TREAT ANALYSIS; MAXIMUM ALLOWABLE INFERIORITY MARGIN; MULTIPLE HYPOTHESIS TESTING; NONINFERIORITY TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

CONTROLLED CLINICAL TRIALS; MODELS, THEORETICAL;

EID: 2642562766     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120037183     Document Type: Article

References (25)

1. Blackwelder, W. C. (1982). "Proving the Null Hypothesis" in clinical trials. Controlled Clin. Trials 3:345-353.
2. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority 2000. http://www.eudra. org/emea.html.
3. Dunnett, C. W., Gent, M. (1977). Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 Tables. Biometrics 3:593-602.
4. Dunnett, C. W., Tamhane, A. C. (1997). Multiple testing to establish superiority/ equivalence of a new treatment compared with kappa standard treatments. Statist. Med. 16(21):2489-2506.
5. Ebbutt, A. F., Frith, L. (1998). Practical issues in equivalence trials. Statist. Med. 17:1691-1701.
6. Ellenberg, S. S., Temple, R. (2000). Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases. Ann. Internal Med. 133:464-470.
7. Fisher, L. D., Gent, M., Bηller, H. R. (2001). Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Amer. Heart J. 141:26-32.
8. Fleming, T. R. (1987). Treatment evaluation in active control studies. Cancer Treatment Rep. 71:1061-1064.
9. Fleming, T. R. (1990). Evaluation of active control trials in AIDS. J. Acquired Immune Deficiency Syndromes 3(Suppl. 2):S82-S87.
10. Gould, A. L. (1991). Another view of active-controlled trials. Controlled Clin. Trials 12:474-485.
11. Hasselblad, V., Kong, D. F. (2001). Statistical methods for comparison to placebo in active-control trials. Drug Inf. J. 35:435-449.
12. Holmgren, E. B. (1999). Establishing equivalence by showing that a prespecified percentage of the effect of the active control over placebo is maintained. J. Biopharmaceutical Statist. 9(4):651-659.
13. Hung, H. M. J., Wang, S. J., Tsong, Y., Lawrence, J., O'Neill, R. (2003). Some fundamental issues with non-inferiority testing in active controlled trials. Statist. Med. 22(2):213-225.
14. Morikawa, T., Yoshida, M. (1995). A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence. J. Biopharmaceutical Statist. 5(3):297-306.
15. Rohmel, J. (1998). Therapeutic equivalence investigations: Statistical considerations. Statist. Med. 17:1703-1714.
16. Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Tsou, H. H. (2003). Design and analysis of non-inferiority mortality trials in oncology. Statist. Med. 22(2): 239-264.
17. Simon, R. (1999). Bayesian design and analysis of active control clinical trials. Biometrics 55:484-487.
18. Temple, R. (1983). Difficulties in evaluating positive control trials. In: Proceedings of the Biopharmaceutical Section of the American Statistical Association, American Statistical Association, Alexandria, VA, USA, pp. 48-54.
19. Temple, R. (1996). Problems in interpreting active control equivalence trials. Accountability Res. 4:267-275.
20. Temple, R., Ellenberg, S. S. (2000). Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues. Ann. Internal Med. 133:455-463.
21. Tsong, Y., Wang, S. J., Hung, H. M. J., Cui, L. (2003). Statistical issues on objective, design and analysis of non-inferiority active controlled clinical trial. J. Biopharmaceutical Statist. 13(1):29-42.
22. Wang, S. J., Hung, H. M. J. (2003). Assessing treatment efficacy in non-inferiority trial. Controlled Clin. Trials 24(2):147-155.
23. Wang, S. J., Hung, H. M. J., Tsong, Y., Cui, L., Nuri, W. A. (1997). Changing the study objective in clinical trials. In: Proceedings of the Biopharmaceutical Section of the American Statistical Association, American Statistical Association, Alexandria, VA, USA, pp. 64-69.
24. Wang, S. J., Hung, H. M. J., Tsong, Y., Cui, L. (2001). Group sequential testing for superiority and non-inferiority hypotheses in active controlled clinical trials. Statist. Med. 20:1903-1912.
25. Wang, S. J., Hung, H. M. J., Tsong, Y. (2002). Utility and pitfall of some statistical methods in active controlled clinical trials. Controlled Clin. Trials 23:15-28.